Bioprocess Automation Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The bioprocess automation market size has grown rapidly in recent years. It will grow from $5.67 billion in 2024 to $6.37 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to increased efficiency, cost reduction, risk mitigation, rising demand for remote monitoring and control, and reduced labor dependency.

The bioprocess automation market size is expected to see rapid growth in the next few years. It will grow to $10.27 billion in 2029 at a compound annual growth rate (CAGR) of 12.7%. The growth in the forecast period can be attributed to enhanced productivity, regulatory compliance, process optimization, predictive maintenance predictive maintenance, and real-time analytics. Major trends in the forecast period include integration of ai and machine learning, modular bioprocessing, process control strategies for gene therapy, process control strategies for gene therapy, and data analytics and visualization.

The increasing number of personalized medicines is expected to fuel the growth of the bioprocess automation market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, practices, interventions, and treatments to the individual characteristics of each patient. Bioprocess automation helps personalized medicine by enabling precision and scalability in producing patient-specific drugs. For instance, according to Personalized Medicine Coalition, a US-based professional membership organization, in 2022, approving 12 new personalized medicines represented approximately 34% of all newly approved therapies, indicating a substantial increase from previous years. Therefore, the increasing number of personalized medicines is driving the growth of the bioprocess automation market.

Major companies operating in the bioprocess automation market are developing innovative solutions, such as bioreactors to simplify bioprocessing operations. A bioreactor is an engineered system or device that provides an optimal and controlled environment for biological and chemical reactions. For instance, in April 2023, Cytiva, a US-based technology company that provides technologies and services that help advance and accelerate the development and manufacture of therapeutics, launched X-platform bioreactors to simplify single-use upstream bioprocessing operations. It is easy to operate, flexible, and more efficient in the process. It was first offered in 50 and 200 L capacities. They can increase process efficiency through ergonomic improvements, production capability, and simplified supply chain operations. The X-platform bioreactors can be used to manufacture cell and gene therapies as well as viral vectors, in addition to monoclonal antibodies (mAbs).

In April 2022, MilliporeSigma, a US-based life science division of Merck KGaA, acquired Lonza’s Modular Automated Sampling Technology (MAST) platform for an undisclosed amount. This acquisition is designed to enhance MilliporeSigma’s position in the bioprocessing market by expanding its portfolio of tools for biopharmaceutical manufacturing. By integrating the MAST platform, MilliporeSigma aims to offer more advanced and automated solutions for the pharmaceutical, biotechnology, and nutrition sectors. Lonza, a Switzerland-based company, is a key player in the manufacturing industry serving these sectors. This move strengthens MilliporeSigma's capabilities in the rapidly growing bioprocessing industry.

Major companies operating in the bioprocess automation market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Corporation, Danaher Corporation, Amgen Inc., Merck KGaA, Parker-Hannifin Corporation, CSL Behring LLC, Rockwell Automation Inc., Agilent Technologies Inc., Lonza Group AG, Waters Corporation, Getinge AB, Eppendorf AG, Repligen Corporation, BIONET Research S.A., Flotek Industries Inc., Pierre Guerin SAS, Bioengineering AG, Genedata AG, ILS Automation, INFORS AG, Synthace Limited, Automated Control Concepts Inc., BlueSens gas sensor GmbH, DISTek Integration Inc., Securecell AG, Flownamics Analytical Instruments Inc., Inscripta Inc., PendoTECH Inc., Sartorius Stedim Biotech S.A.

North America was the largest region in the bioprocess automation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the bioprocess automation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bioprocess automation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bioprocess automation market includes revenues earned by entities by providing services such as process automation, instrumentation and control systems, training and support services, and maintenance and upgrades. The market value includes the value of related goods sold by the service provider or included within the service offering. The bioprocess automation market also includes sales of bioreactors, fermenters, laboratory information management systems (LIMS), and integrated bioprocess platforms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Bioprocess automation is using automated systems to monitor and control the bioprocessing workflow, which involves living cells, organisms, or components to produce biological products such as biopharmaceuticals. Biopharmaceutical businesses use bioprocess automation for better process control and optimization, higher product quality, decreased variability, increased throughput and efficiency, cost savings, and scalability.

The main components of bioprocess automation are sensors, actuators, and controllers. Sensors are devices that detect and respond to inputs from the physical environment, converting them into electronic signals, which are used to monitor various parameters such as temperature, pH, dissolved oxygen, and pressure. The scale of operation includes preclinical operations, clinical operations, and commercial operations with batch, fed-batch, and perfusion modes of compatibility with bioprocessing systems include single-use systems, stainless steel, and others.

The main components of bioprocess automation are sensors, actuators, and controllers. Sensors are devices that detect and respond to inputs from the physical environment, converting them into electronic signals, which are used to monitor various parameters such as temperature, pH, dissolved oxygen, and pressure. The scale of operation includes preclinical operations, clinical operations, and commercial operations with batch, fed-batch, and perfusion modes of compatibility with bioprocessing systems include single-use systems, stainless steel, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.